Adverum Biotechnologies, Inc.
ADVM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $92 | $437 | $336 | $1,731 |
| - Cash | $61 | $75 | $68 | $34 |
| + Debt | $92 | $74 | $107 | $103 |
| Enterprise Value | $123 | $436 | $375 | $1,800 |
| Revenue | $1 | $4 | $0 | $8 |
| % Growth | -72.2% | – | -100% | – |
| Gross Profit | $1 | $4 | $0 | $8 |
| % Margin | 100% | 100% | – | 100% |
| EBITDA | -$136 | -$123 | -$151 | -$141 |
| % Margin | -13,550.6% | -3,424.9% | – | -1,886.4% |
| Net Income | -$131 | -$122 | -$155 | -$146 |
| % Margin | -13,092.7% | -3,392.1% | – | -1,940.5% |
| EPS Diluted | -6.62 | -2.02 | -2.67 | -1.48 |
| % Growth | -227.7% | 24.3% | -80.4% | – |
| Operating Cash Flow | -$92 | -$91 | -$108 | -$108 |
| Capital Expenditures | -$0 | -$1 | -$12 | -$15 |
| Free Cash Flow | -$93 | -$92 | -$120 | -$123 |